Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: June 25, 2010
Last updated: June 22, 2014
Last verified: June 2014